ASP-0113

N/A

Report date: 2023/04/10 14:04:04

Base Information

Drug NameASP-0113

Drug Alias NameASP0113 CMV Therapeutic VaccineCytomegalovirus DNA vaccine bivalentTransVaxVCL-CB01ASP-0113

ClassificationVaccines > Development/production technology > Nucleic acid vaccine > DNA vaccineVaccines > Application > Prophylactic vaccineVaccines > Vaccine type > Multivalent vaccine

Mechanisms of ActionImmunostimulants

TargetsNot applicable

Therapy Area/IndicationsRejection of renal transplantationSpinal FusionMyelodysplastic Syndromes +[9]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBelgiumCanadaUnited States +[11]

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaN/A

Originator CompaniesFresh Tracks Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesAstellas Pharma Global Development Inc

Inactive CompaniesAstellas Pharma Inc

Active IndicationsSpinal FusionCytomegalovirus Infections

Inactive IndicationsRejection of renal transplantationMyelodysplastic SyndromesLymphoma, Non-Hodgkin +[7]

Other Information

ATC CodeN/A